Oncology Nursing Minimum Data Set (ONMDS): can we hypothesize a set of prevalent Nursing Sensitive Outcomes (NSO) in cancer patients?

Milani, A.; Mauri, S.; Gandini, S.; Magon, G.
October 2013
Ecancermedicalscience;2013, Vol. 7 Issue 334-360, p1
Academic Journal
Background: The nursing minimum data set (NMDS) was created in 1977 in the United States to collect uniform standardised data that could be comparable among different nursing areas or patients. So far, in the literature, an NMDS in an oncology setting has not yet been described. Considering an oncology nursing minimum data set (ONMDS), which data could be chosen to define this tool regarding cancer patient care? Material and methods: At the European Institute of Oncology (IEO), 20 experienced oncology nurses representing surgical, medical, and critical areas participated in a nursing record working group. All nurses followed an educational course on NMDS, and they shared clinical experiences to find which data common among different areas could be useful to care. To identify these data, nurses considered three issues: what is nursing care for nurses in the IEO? What is the nurses' responsibility in the IEO? What is the organisational nursing model in the IEO? Nurses in the IEO are autonomous in decision making and recognised by patients and by a multi-professional team; the organisational nursing model is primary nursing with patient-centred care. Nursing data must therefore show the quality and results of this care. With this in mind, the working group decided to orient the ONMDS toward nursing-sensitive outcomes (NSOs), meeting also with psychologists, physiotherapists, and dieticians. Nurses analysed Oncology Nursing Society outcomes, and through focus groups, experiential meetings, role playing, and case studies, they integrated them with other NSOs. Results: The ONMDS is composed of 49 NSOs recognised as the most common and frequent oncologic outcomes regardless of the treatment that the patient undergoes. These outcomes were clustered into 15 categories. The categories are: gastrointestinal outcomes, genitourinary outcomes, respiratory outcomes, skin outcomes, fluid and electrolyte balance outcomes, neurological outcomes, security, functional status, vascular access outcomes, nutritional status, pain, psychosocial discomfort, activities of daily living (ADL), instrumental activities daily living (IADL), and self-care outcomes. Conclusions: Efforts to identify an ONMDS based on NSOs allow us to develop an tool that can standardise language, assessment, and intervention, but overall could be used to measure nursing care. To evaluate these potentialities, the ONMDS was introduced into nursing records, and it was tested with a pre-post research study.


Related Articles

  • European Institute of Oncology inaugurated in Milan. Vanchieri, Cori // JNCI: Journal of the National Cancer Institute;6/1/94, Vol. 86 Issue 11, p827 

    Reports on the inauguration of the European Institute of Oncology in Milan, Italy. Staff; Agreements with European academic institutes regarding career issues.

  • Correlation between administered treatment and patient's living will. Andreoni, B.; Goldhirsch, A.; Orecchia, R.; Venturino, M.; Spirito, R.; Tadini, L.; Corbellini, C.; Bertani, E.; Veronesi, U. // Ecancermedicalscience;2009, Vol. 3, p1 

    Respecting the wishes of an adequately informed patient should be a priority in any health structure. A patient with advanced or terminal cancer should be allowed to express their will during the most important phases of their illness. Unfortunately, this is seldom the case, and in general...

  • Case mix at the European Institute of Oncology: first report of the Tumour Registry, 2000-2002. Botteri, E.; Iodice, S.; Maisonneuve, P.; Alfieri, M.; Burzoni, N.; Manghi, L.; Martinetti, M.; Montanari, B.; Albertazzi, E.; Bazolli, B.; Rotmensz, N. // Ecancermedicalscience;2009, Vol. 3, p1 

    Introduction: An institutional and centralized hospital-based tumour registry (TR) is the ideal supporting tool for the organization and management of clinical data in a comprehensive cancer centre. The purpose of this paper is to describe the development of the TR at the European Institute of...

  • The role of [18F]FDG-PET/CT in staging and treatment planning for volumetric modulated Rapidarc radiotherapy in cervical cancer: experience of the European Institute of Oncology, Milan, Italy. Lazzari, Roberta; Cecconi, Agnese; Jereczek-Fossa, Barbara A.; Travaini, Laura Lavinia; Dell' Acqua, Veronica; Cattani, Federica; Rizzo, Stefania; Fodor, Cristiana; Landoni, Fabio; Orecchia, Roberto // Ecancermedicalscience;2014, Vol. 8 Issue 381-412, p1 

    Rationale: to evaluate the role of 18F-fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) integrated with computer tomography (CT) scan [18F]FDG-PET/CT in the staging and target volume definition in Intensity Modulated RapidarcTM Delivery (RA-IMRT) in cervical cancer. Methods: From...

  • Report from the Melanoma Independent Board First Melanoma MIB Conference, 21-22 October 2013. Testori, A.; Ascierto, P.; Chiarion Sileni, V.; De Lorenzo, F.; Pelicci, P. G.; Rossi, C. R. // Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1 

    The Melanoma Independent Board (MIB) held its first conference from 21 to 22 October, 2013, in Rome, Italy. Like the MIB itself, the conference brought together specialists from all aspects of cancer care: doctors, patient associations, journalists, and representatives from local government,...

  • Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Pruneri, G.; Vingiani, A.; Bagnardi, V.; Rotmensz, N.; De Rose, A.; Palazzo, A.; Colleoni, A. M.; Goldhirsch, A.; Viale, G. // Annals of Oncology;Feb2016, Vol. 27 Issue 2, p249 

    Background: Although tumor-infiltrating lymphocytes (TILs) have been associated with a favorable prognosis in triplenegative breast cancer (TNBC) patients, this marker is not currently considered robust enough for entering the clinical practice. In the present study, we assessed the clinical...

  • Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum].  // Breast Cancer: Targets & Therapy;Mar2018, Vol. 11, p51 

    No abstract available.

  • Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology. Biffi, R.; Orsi, F.; Zampino, M. G.; Chiappa, A.; Fazio, N.; De Braud, F.; Bonomo, G.; Monfardini, L.; Vigna, P. D.; Luca, F.; Bodei, L.; Bartolomei, M.; Catalano, G.; Leonardi, M. C.; Ferrari, M.; Andreoni, B.; Goldhirsch, A.; Paganelli, G.; Orecchia, R. // Ecancermedicalscience;2008, Vol. 2, p1 

    Background: An institutional task force on upper gastrointestinal tumours is active at the European Institute of Oncology (EIO). Members decided to collate the institutional guidelines on management of liver tumours (primary and metastatic) into a document. This article is aimed at presenting...

  • Delcath enters launch and training agreements with IEO.  // Medical Device Daily;11/28/2011, Vol. 15 Issue 226, p2 

    The article reports that Delcath Systems of New York has entered into an initial launch and training agreement with the European Institute of Oncology (Instituto Europeo de Oncologia, or IEO), a European cancer treatment and research center in Milan, Italy, for the Delcath Hepatic Chemostat...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics